Coronary disease & ACSCohort study
GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence
- Retrospective cohort study
- nationwide registry
- propensity-score matched
Authors' conclusion
GLP-1RA therapy after MI or stroke in T2D was associated with substantially lower risks of MACE, cardiovascular and all-cause death in real-world practice.
Study context
- Population
- Patients with T2D after incident nonfatal myocardial infarction (MI) or ischemic stroke, Czech registry, 2015–20242 matched cohorts
- Exposure
- GLP-1RA users vs non-users
- Outcome
- MACE:
- Nonfatal MI
- Nonfatal stroke
- CV death
Main finding
As reported in the abstract
MACE
GLP-1RA vs Non-usersHazard ratio (95% CI)
MI cohort (n = 2,271; 401 GLP-1RA; median follow-up 35 months)
0.7(0.52–0.93)
stroke cohort (n = 2,235; 385 GLP-1RA; median follow-up 27 months)
0.71(0.54–0.94)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause death — GLP-1RA vs Non-users · MI cohort | 0.61 (0.47–0.80) | |
| All-cause death — GLP-1RA vs Non-users · stroke cohort | 0.59 (0.46–0.76) | |
| CV death — GLP-1RA vs Non-users · MI cohort | 0.54 (0.36–0.80) | |
| CV death — GLP-1RA vs Non-users · stroke cohort | 0.55 (0.37–0.81) | |
| 0.20.5125Hazard ratio (log scale) |
GLP-1RA initiation after MI or stroke in T2D
- GLP-1RA therapy initiated
- ∼2%
Original publication
GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence. Eur J Prev Cardiol. Published 7 January 2026. doi:10.1093/eurjpc/zwag002
Summarised from the published abstract; every number is checked against it